Table 1 |
|||||
|
Quinolone-specific resistance mechanisms in 2005 and 2009 nalidixic acid-resistant isolates |
|||||
|
Number of isolates |
Nalidixic acid MIC |
Ciprofloxcin |
GyrA SNPs |
ParC SNPs |
Horizontally-acquired |
|
|
|||||
|
2005 |
|||||
|
|
|||||
|
3 |
8-32 |
Sensitive |
S83L |
- |
- |
|
|
|||||
|
1 |
1024 |
Resistant |
S83L, D87N |
S80I |
- |
|
|
|||||
|
2009 |
|||||
|
|
|||||
|
2 |
256 |
Sensitive |
D101G* |
- |
- |
|
|
|||||
|
1 |
16 |
Sensitive |
S83L |
- |
- |
|
|
|||||
|
1 |
1024 |
Resistant |
S83L, D87N |
- |
- |
|
|
|||||
|
4 |
> 1024 |
Resistant |
S83L, D87N |
S80I |
- |
|
|
|||||
|
1 |
64 |
Sensitive |
- |
S94F* |
- |
|
|
|||||
|
1 |
256 |
Sensitive |
- |
V54I* |
- |
|
|
|||||
|
1 |
32 |
Resistant |
- |
Y74C* |
qnrS1 |
|
|
|||||
|
5 |
16-256 |
Resistant |
- |
- |
qnrS1 |
|
|
|||||
|
*Previously unreported SNP for which there is no evidence of functional contribution to resistance |
|||||
|
Lamikanra et al. BMC Infectious Diseases 2011 11:312 doi:10.1186/1471-2334-11-312 |
|||||